Skip to main content
Premium Trial:

Request an Annual Quote

Ayala, ArcherDx Partner to Advance CDx for Notch Inhibitors

NEW YORK – Ayala Pharmaceuticals and ArcherDx said today they will work together to develop companion diagnostics that can gauge whether cancer patients have Notch-activating genetic mutations and fusions and will respond to certain targeted drugs.  

Within the collaboration, Boulder, Colorado-based ArcherDx will provide companion diagnostic solutions to identify best responders to Notch inhibitors that Wilmington, Delaware-based Ayala is developing. For example, the precision cancer drug developer is currently advancing the investigational therapeutic AL101 through Phase II trials as a treatment for adenoid cystic carcinoma characterized by Notch-activating mutations.

ArcherDx, meanwhile, has been looking to expand its CDx footprint. In May, the company raised $60 million in a Series B financing round that it said would go toward scaling its companion diagnostics operations. 

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.